Donor NK cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation

Journal of Immunology

Volumn 189, Issue 4, 2012, Pages 1661-1670

  Hu, Bo ^a   Bao, Guangming ^a   Zhang, Yinsheng ^a   Lin, Dandan ^a   Wu, Yan ^a   Wu, Depei ^a   Liu, Haiyan ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; INTERLEUKIN 2; MESSENGER RNA; RECOMBINANT INTERLEUKIN 15;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN FUNCTION; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; ENGRAFTMENT; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; HYDRODYNAMICS BASED TRANSFECTION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; LIVER PARENCHYMA; LYMPHOCYTE FUNCTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; NONMYELOABLATIVE ALLOGENIC BONE MARROW TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW TRANSPLANTATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-15; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864799079     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1103199     Document Type: Article

References (32)

1. Aversa, F., A. Tabilio, A. Terenzi, A. Velardi, F. Falzetti, C. Giannoni, R. Iacucci, T. Zei, M. P. Martelli, C. Gambelunghe, et al. 1994. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84: 3948-3955.
2. Bachar-Lustig, E., N. Rachamim, H. W. Li, F. Lan, and Y. Reisner. 1995. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat. Med. 1: 1268-1273.
3. Reisner, Y., and M. F. Martelli. 1995. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol. Today 16: 437-440.
4. Biron, C. A., K. B. Nguyen, G. C. Pien, L. P. Cousens, and T. P. Salazar-Mather. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17: 189-220. (Pubitemid 29241123)
5. Cerwenka, A., J. L. Baron, and L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98: 11521-11526. (Pubitemid 32928761)
6. Hu, B., Y. He, Y. Wu, G. Bao, H. Liu, L. A. Welniak, and W. J. Murphy. 2010. Activated allogeneic NK cells as suppressors of alloreactive responses. Biol. Blood Marrow Transplant. 16: 772-781.
7. Olson, J. A., D. B. Leveson-Gower, S. Gill, J. Baker, A. Beilhack, and R. S. Negrin. 2010. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood 115: 4293-4301.
8. Velardi, A., L. Ruggeri, A. Mancusi, F. Aversa, and F. T. Christiansen. 2009. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr. Opin. Immunol. 21: 525-530.
9. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100. (Pubitemid 34229476)
10. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912. (Pubitemid 41396891)
11. bright subset. Blood 97: 3146-3151.
12. Fehniger, T. A., and M. A. Caligiuri. 2001. Interleukin 15: biology and relevance to human disease. Blood 97: 14-32. (Pubitemid 32061238)
13. Cavazzana-Calvo, M., S. Hacein-Bey, G. de Saint Basile, C. De Coene, F. Selz, F. Le Deist, and A. Fischer. 1996. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from γ c transduced severe combined immunodeficiency X1 bone marrow cells. Blood 88: 3901-3909. (Pubitemid 26383114)
14. DiSanto, J. P., W. Müller, D. Guy-Grand, A. Fischer, and K. Rajewsky. 1995. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γ chain. Proc. Natl. Acad. Sci. USA 92: 377-381.
15. Kennedy, M. K., M. Glaccum, S. N. Brown, E. A. Butz, J. L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C. R. Willis, et al. 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191: 771-780.
16. Lodolce, J. P., D. L. Boone, S. Chai, R. E. Swain, T. Dassopoulos, S. Trettin, and A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9: 669-676. (Pubitemid 28557595)
17. Suzuki, H., G. S. Duncan, H. Takimoto, and T. W. Mak. 1997. Abnormal development of intestinal intraepithelial lymphocytes and peripheral natural killer cells in mice lacking the IL-2 receptor b chain. J. Exp. Med. 185: 499-505. (Pubitemid 27078368)
18. Barao, I., M. Alvarez, D. Redelman, J. M. Weiss, J. R. Ortaldo, R. H. Wiltrout, and W. J. Murphy. 2011. Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation. Biol. Blood Marrow Transplant. 17: 1754-1764.
19. Koh, C. Y., J. R. Ortaldo, B. R. Blazar, M. Bennett, and W. J. Murphy. 2003. NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood 102: 4067-4075. (Pubitemid 37486990)
20. Asai, O., D. L. Longo, Z. G. Tian, R. L. Hornung, D. D. Taub, F. W. Ruscetti, and W. J. Murphy. 1998. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Invest. 101: 1835-1842. (Pubitemid 28226101)
21. Shlomchik, W. D., M. S. Couzens, C. B. Tang, J. McNiff, M. E. Robert, J. Liu, M. J. Shlomchik, and S. G. Emerson. 1999. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285: 412-415. (Pubitemid 29343964)
22. Huntington, N. D., N. Legrand, N. L. Alves, B. Jaron, K. Weijer, A. Plet, E. Corcuff, E. Mortier, Y. Jacques, H. Spits, and J. P. Di Santo. 2009. IL-15 transpresentation promotes human NK cell development and differentiation in vivo. J. Exp. Med. 206: 25-34.
23. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. (Pubitemid 35231542)
24. +T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99: 16168-16173.
25. Berger, C., M. Berger, R. C. Hackman, M. Gough, C. Elliott, M. C. Jensen, and S. R. Riddell. 2009. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 114: 2417-2426.
26. Alpdogan, O., J. M. Eng, S. J. Muriglan, L. M. Willis, V. M. Hubbard, K. H. Tjoe, T. H. Terwey, A. Kochman, and M. R. van den Brink. 2005. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 105: 865-873. (Pubitemid 40070777)
27. Pillet, A. H., F. Bugault, J. Thèze, L. A. Chakrabarti, and T. Rose. 2009. A programmed switch from IL-15- to IL-2-dependent activation in human NK cells. J. Immunol. 182: 6267-6277.
28. Szczepanski, M. J., M. Szajnik, A. Welsh, K. A. Foon, T. L. Whiteside, and M. Boyiadzis. 2010. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol. Immunother. 59: 73-79.
29. Zhang, C., J. Zhang, J. Niu, J. Zhang, and Z. Tian. 2008. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 42: 128-136.
30. Blaser, B. W., S. Roychowdhury, D. J. Kim, N. R. Schwind, D. Bhatt, W. Yuan, D. F. Kusewitt, A. K. Ferketich, M. A. Caligiuri, and M. Guimond. 2005. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood 105: 894-901. (Pubitemid 40070781)
31. Roychowdhury, S., B. W. Blaser, A. G. Freud, K. Katz, D. Bhatt, A. K. Ferketich, V. Bergdall, D. Kusewitt, R. A. Baiocchi, and M. A. Caligiuri. 2005. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood 106: 2433-2435. (Pubitemid 41510817)
32. Thiant, S., M. Labalette, J. Trauet, V. Coiteux, E. de Berranger, J. P. Dessaint, and I. Yakoub-Agha. 2011. Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant. 46: 1374-1381.